Semantic dementia

Summary

Semantic dementia (MONDO:0010857) is a disease caused by variants in MAPT and PSEN1, with 2 cohort genes and 161 clinical trials. Top therapeutic interventions include citalopram, florbetapir, and memantine.

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Causal genes: MAPT (GenCC Strong), PSEN1 (GenCC Strong)
• Cohort genes: 2
• ClinVar variants: 1
• Phenotypes (HPO): 10
• Clinical trials: 161

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		49	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

10 HPO clinical features (Orphanet curated; top 10 by frequency):

HPO ID	Term	Frequency
HP:0002381	Aphasia	Very frequent (80-99%)
HP:0012444	Brain atrophy	Very frequent (80-99%)
HP:0030222	Visual agnosia	Very frequent (80-99%)
HP:0030784	Anomia	Very frequent (80-99%)
HP:0000726	Dementia	Frequent (30-79%)
HP:0002167	Abnormality of speech or vocalization	Frequent (30-79%)
HP:0010522	Dyslexia	Frequent (30-79%)
HP:0010523	Alexia	Frequent (30-79%)
HP:0010526	Dysgraphia	Frequent (30-79%)
HP:0012671	Abulia	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	semantic dementia
Mondo ID	MONDO:0010857
OMIM	600274
Orphanet	100069
DOID	DOID:0051060, DOID:0081391
UMLS	C0338462
MedGen	83268
GARD	0010792
Is cancer (heuristic)	no

Also known as: dementia, frontotemporal · dementia, frontotemporal, with or without parkinsonism · frontotemporal dementia · FTD · semantic primary progressive aphasia · semantic variant PPA

Data availability: 1 ClinVar variant · 3 GenCC gene-disease records · 143 cell lines.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › progressive non-fluent aphasia › semantic dementia

Subtypes (1): frontotemporal dementia, right temporal atrophy variant

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
3036349	NM_001377265.1(MAPT):c.1568G>A (p.Arg523Gln)	MAPT	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 20 · Orphanet: 13 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
MAPT	Strong	Autosomal dominant	semantic dementia	8
PSEN1	Strong	Autosomal dominant	semantic dementia	12

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MAPT	Orphanet:100069	Semantic dementia
MAPT	Orphanet:100070	Progressive non-fluent aphasia
MAPT	Orphanet:240071	Classic progressive supranuclear palsy syndrome
MAPT	Orphanet:240085	Progressive supranuclear palsy-predominant parkinsonism syndrome
MAPT	Orphanet:240094	Progressive supranuclear palsy-pure akinesia with gait freezing syndrome
MAPT	Orphanet:240103	Progressive supranuclear palsy-corticobasal syndrome
MAPT	Orphanet:240112	Progressive supranuclear palsy-progressive non-fluent aphasia syndrome
MAPT	Orphanet:275864	Behavioral variant of frontotemporal dementia
PSEN1	Orphanet:100069	Semantic dementia
PSEN1	Orphanet:100070	Progressive non-fluent aphasia
PSEN1	Orphanet:1020	Early-onset autosomal dominant Alzheimer disease
PSEN1	Orphanet:154	Familial isolated dilated cardiomyopathy
PSEN1	Orphanet:275864	Behavioral variant of frontotemporal dementia

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MAPT	HGNC:6893	ENSG00000186868	P10636	Microtubule-associated protein tau	gencc,clinvar
PSEN1	HGNC:9508	ENSG00000080815	P49768	Presenilin-1	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MAPT	Microtubule-associated protein tau	Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity.
PSEN1	Presenilin-1	Catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein).

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	1	18.3×	0.108
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MAPT	Other/Unknown	no		MAP_tubulin-bd_rpt, Tau, MAP2/MAP4/Tau
PSEN1	Protease	yes		Peptidase_A22A, Pept_A22A_PS1, Preselin/SPP

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cortical plate	1
prefrontal cortex	1
superior frontal gyrus	1
C1 segment of cervical spinal cord	1
corpus callosum	1
middle frontal gyrus	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MAPT	141	broad	marker	cortical plate, superior frontal gyrus, prefrontal cortex
PSEN1	287	ubiquitous	marker	middle frontal gyrus, corpus callosum, C1 segment of cervical spinal cord

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MAPT	7,289
PSEN1	3,732

Intra-cohort edges

A	B	Sources
MAPT	PSEN1	string_interaction

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MAPT	P10636	293
PSEN1	P49768	27

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 21. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Noncanonical activation of NOTCH3	1	713.8×	0.009	PSEN1
Regulated proteolysis of p75NTR	1	519.1×	0.009	PSEN1
NOTCH4 Activation and Transmission of Signal to the Nucleus	1	519.1×	0.009	PSEN1
Caspase-mediated cleavage of cytoskeletal proteins	1	475.8×	0.009	MAPT
TGFBR3 PTM regulation	1	475.8×	0.009	PSEN1
NRIF signals cell death from the nucleus	1	356.9×	0.009	PSEN1
Apoptotic cleavage of cellular proteins	1	237.9×	0.009	MAPT
Apoptotic execution phase	1	237.9×	0.009	MAPT
NOTCH3 Activation and Transmission of Signal to the Nucleus	1	237.9×	0.009	PSEN1
NOTCH2 Activation and Transmission of Signal to the Nucleus	1	219.6×	0.009	PSEN1
Activation of AMPK downstream of NMDARs	1	190.3×	0.009	MAPT
Activated NOTCH1 Transmits Signal to the Nucleus	1	178.4×	0.009	PSEN1
Nuclear signaling by ERBB4	1	173.0×	0.009	PSEN1
EPH-ephrin mediated repulsion of cells	1	109.8×	0.013	PSEN1
Constitutive Signaling by NOTCH1 PEST Domain Mutants	1	98.5×	0.013	PSEN1
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	1	98.5×	0.013	PSEN1
Apoptosis	1	84.0×	0.015	MAPT
Programmed Cell Death	1	73.2×	0.016	MAPT
PKR-mediated signaling	1	70.5×	0.016	MAPT
Degradation of the extracellular matrix	1	58.9×	0.018	PSEN1
Neutrophil degranulation	1	11.5×	0.085	PSEN1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
astrocyte activation	2	991.3×	1e-04	MAPT, PSEN1
synapse organization	2	280.9×	5e-04	MAPT, PSEN1
regulation of synaptic plasticity	2	259.3×	5e-04	MAPT, PSEN1
learning or memory	2	240.7×	5e-04	MAPT, PSEN1
memory	2	183.2×	7e-04	MAPT, PSEN1
plus-end-directed organelle transport along microtubule	1	8426.0×	0.002	MAPT
positive regulation of L-glutamate import across plasma membrane	1	4213.0×	0.002	PSEN1
Cajal-Retzius cell differentiation	1	4213.0×	0.002	PSEN1
smooth endoplasmic reticulum calcium ion homeostasis	1	4213.0×	0.002	PSEN1
neurofibrillary tangle assembly	1	4213.0×	0.002	MAPT
negative regulation of protein localization to mitochondrion	1	4213.0×	0.002	MAPT
negative regulation of gene expression	2	69.1×	0.002	MAPT, PSEN1
protein catabolic process at postsynapse	1	2808.7×	0.003	PSEN1
astrocyte activation involved in immune response	1	2106.5×	0.003	PSEN1
rRNA metabolic process	1	2106.5×	0.003	MAPT
obsolete synaptic vesicle targeting	1	2106.5×	0.003	PSEN1
axonal transport	1	2106.5×	0.003	MAPT
positive regulation of protein localization to synapse	1	2106.5×	0.003	MAPT
DNA damage response	2	53.5×	0.003	MAPT, PSEN1
obsolete sequestering of calcium ion	1	1685.2×	0.003	PSEN1
negative regulation of mitochondrial fission	1	1685.2×	0.003	MAPT
regulation of long-term synaptic depression	1	1685.2×	0.003	MAPT
positive regulation of amyloid fibril formation	1	1685.2×	0.003	PSEN1
positive regulation of coagulation	1	1404.3×	0.004	PSEN1
regulation of microtubule-based movement	1	1404.3×	0.004	MAPT
intracellular distribution of mitochondria	1	1203.7×	0.004	MAPT
regulation of mitochondrial fission	1	1053.2×	0.004	MAPT
Notch receptor processing	1	936.2×	0.004	PSEN1
amyloid-beta formation	1	936.2×	0.004	PSEN1
L-glutamate import across plasma membrane	1	936.2×	0.004	PSEN1

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
MAPT	BEPRIDIL
PSEN1	NIROGACESTAT

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MAPT	449	4
PSEN1	8	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BEPRIDIL	4	MAPT
PHENYLBUTAZONE	4	MAPT
CEFOTAXIME SODIUM	4	MAPT
DIENESTROL	4	MAPT
PROGESTERONE	4	MAPT
CLOTRIMAZOLE	4	MAPT
CHOLECALCIFEROL	4	MAPT
LATANOPROST	4	MAPT
CHLORTHALIDONE	4	MAPT
FLUORESCEIN	4	MAPT
OXCARBAZEPINE	4	MAPT
NABUMETONE	4	MAPT
GLIPIZIDE	4	MAPT
AMIODARONE HYDROCHLORIDE	4	MAPT
TRICLABENDAZOLE	4	MAPT
MESORIDAZINE	4	MAPT
INDIGOTINDISULFONATE	4	MAPT
TRIHEXYPHENIDYL HYDROCHLORIDE	4	MAPT
IMIPRAMINE	4	MAPT
FURAZOLIDONE	4	MAPT
DROPERIDOL	4	MAPT
ARIPIPRAZOLE	4	MAPT
RALOXIFENE HYDROCHLORIDE	4	MAPT
IDARUBICIN	4	MAPT
ACETAMINOPHEN	4	MAPT
ACITRETIN	4	MAPT
CISPLATIN	4	MAPT
CLOBETASOL PROPIONATE	4	MAPT
AMINOSALICYLIC ACID	4	MAPT
TETRABENAZINE	4	MAPT

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PSEN1	557	Binding:538, Functional:12, ADMET:6, Unclassified:1
MAPT	184	Binding:180, Functional:4

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
MAPT	184
PSEN1	557

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BEPRIDIL	4	MAPT
PHENYLBUTAZONE	4	MAPT
CEFOTAXIME SODIUM	4	MAPT
DIENESTROL	4	MAPT
PROGESTERONE	4	MAPT
CLOTRIMAZOLE	4	MAPT
CHOLECALCIFEROL	4	MAPT
LATANOPROST	4	MAPT
CHLORTHALIDONE	4	MAPT
FLUORESCEIN	4	MAPT
OXCARBAZEPINE	4	MAPT
NABUMETONE	4	MAPT
GLIPIZIDE	4	MAPT
AMIODARONE HYDROCHLORIDE	4	MAPT
TRICLABENDAZOLE	4	MAPT
MESORIDAZINE	4	MAPT
INDIGOTINDISULFONATE	4	MAPT
TRIHEXYPHENIDYL HYDROCHLORIDE	4	MAPT
IMIPRAMINE	4	MAPT
FURAZOLIDONE	4	MAPT
DROPERIDOL	4	MAPT
ARIPIPRAZOLE	4	MAPT
RALOXIFENE HYDROCHLORIDE	4	MAPT
IDARUBICIN	4	MAPT
ACETAMINOPHEN	4	MAPT
ACITRETIN	4	MAPT
CISPLATIN	4	MAPT
CLOBETASOL PROPIONATE	4	MAPT
AMINOSALICYLIC ACID	4	MAPT
TETRABENAZINE	4	MAPT

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	MAPT, PSEN1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 161.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	122
PHASE2	14
PHASE1	8
PHASE1/PHASE2	7
PHASE4	4
PHASE3	3
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00950430	PHASE4	ENROLLING_BY_INVITATION	Imaging of Brain Amyloid Plaques in the Aging Population
NCT06093126	PHASE4	RECRUITING	Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
NCT00376051	PHASE4	COMPLETED	Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia
NCT00545974	PHASE4	COMPLETED	Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
NCT00594737	PHASE3	COMPLETED	Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
NCT03682185	PHASE3	COMPLETED	The Healthy Patterns Sleep Study
NCT04374136	PHASE3	TERMINATED	A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
NCT04220021	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
NCT04408625	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
NCT04747431	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
NCT05262023	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05374278	PHASE1/PHASE2	RECRUITING	First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
NCT05742698	PHASE2	RECRUITING	Nabilone for Agitation in Frontotemporal Dementia
NCT06064890	PHASE1/PHASE2	RECRUITING	A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
NCT06604520	PHASE2	RECRUITING	Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
NCT07154485	PHASE2	NOT_YET_RECRUITING	Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
NCT00416169	PHASE2	COMPLETED	A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia
NCT01890343	PHASE2	COMPLETED	Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer’s Disease and Normal Controls.
NCT01937013	PHASE2	COMPLETED	Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
NCT02676843	PHASE2	COMPLETED	Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
NCT02862210	PHASE2	COMPLETED	Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
NCT03260920	PHASE2	UNKNOWN	Intranasal Oxytocin for Frontotemporal Dementia
NCT03987295	PHASE2	COMPLETED	A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
NCT04489017	PHASE2	COMPLETED	Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled Trial
NCT04931862	PHASE1/PHASE2	TERMINATED	Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
NCT04937452	PHASE2	COMPLETED	Dopaminergic Therapy for Frontotemporal Dementia Patients
NCT04993755	PHASE2	COMPLETED	A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
NCT05683860	PHASE1/PHASE2	TERMINATED	Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
NCT05184569	PHASE1	RECRUITING	Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
NCT05315661	PHASE1	ACTIVE_NOT_RECRUITING	The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia
NCT01386333	PHASE1	COMPLETED	Safety Study of Intranasal Oxytocin in Frontotemporal Dementia
NCT01623284	PHASE1	COMPLETED	PiB PET Scanning in Speech and Language Based Dementias
NCT03040713	PHASE1	COMPLETED	Flortaucipir PET Imaging in Subjects With FTD
NCT03636204	PHASE1	COMPLETED	A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
NCT06226064	PHASE1	COMPLETED	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
NCT06705192	PHASE1	COMPLETED	Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001
NCT06891716	EARLY_PHASE1	RECRUITING	[18F]ACI-19626 PET in TDP-43 Proteinopathies
NCT03510572	EARLY_PHASE1	COMPLETED	Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
NCT03625128	EARLY_PHASE1	COMPLETED	18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer’s Disease, Other Dementias and Normal Controls
NCT01353430	Not specified	RECRUITING	Characterization of Inclusion Body Myopathy Associated With Paget’s Disease of Bone and Frontotemporal Dementia (IBMPFD)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CITALOPRAM	4	3
FLORBETAPIR	4	3
MEMANTINE	4	3
FLORTAUCIPIR F 18	4	2
ESCITALOPRAM	4	1
FLUDEOXYGLUCOSE F 18	4	1
FLUTEMETAMOL	4	1
GALANTAMINE HYDROBROMIDE	4	1
LEMBOREXANT	4	1
LITHIUM CARBONATE	4	1
NABILONE	4	1
ROTIGOTINE	4	1
VORTIOXETINE	4	1
LATOZINEMAB	3	3
FLUORIDE ION F-18	3	1
LEUCINE	3	1
VERDIPERSTAT	3	1
COSFROVIXIMAB	2	1
PITTSBURGH COMPOUND B	2	1
CHEMBL498563	0	1
CHEMBL5189046	0	1
CHEMBL104383	0	1
F-18	0	1